Trials / Unknown
UnknownNCT03835507
Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 64 (estimated)
- Sponsor
- Hanyang University Seoul Hospital · Academic / Other
- Sex
- All
- Age
- 25 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Erythropoietin is neuroprotective in animal models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to determine the safety and feasibility of repetitive high-dose recombinant human erythropoietin (rhEPO) therapy in ALS patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant human erythropoietin(rhEPO) | Injection of erythropoietin every months (total 12 months) |
Timeline
- Start date
- 2016-06-20
- Primary completion
- 2020-12-01
- Completion
- 2025-12-01
- First posted
- 2019-02-08
- Last updated
- 2019-02-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03835507. Inclusion in this directory is not an endorsement.